Market Place
Sourcing Support
Sutro Biopharma Announces Luvelta Dose & REFR?ME-O1 Results
10 Dec 2024 //
GLOBENEWSWIRE
Sutro Biopharma Reports Q3 2024 Financial Results & Update
13 Nov 2024 //
GLOBENEWSWIRE
Sutro Biopharma Presents ADC Data at World ADC Conference
04 Nov 2024 //
GLOBENEWSWIRE
Sutro Biopharma to Initiate REFR?ME-P1 Trial for Pediatric AML
01 Nov 2024 //
GLOBENEWSWIRE
Sutro Bio Highlights ADC Innovation And Pipeline At Research Forum
10 Oct 2024 //
GLOBENEWSWIRE
Sutro Biopharma Announces Inducement Grant
20 Sep 2024 //
GLOBENEWSWIRE
Sutro Biopharma Announces Luvelta Combo Phase 1b Data At ESMO 2024
14 Sep 2024 //
GLOBENEWSWIRE
Sutro Biopharma To Host Research Forum On ADC Innovation October 10, 2024
11 Sep 2024 //
GLOBENEWSWIRE
Sutro Biopharma Initiates REFR?ME-L1 Phase 2 Trial For NSCLC
22 Aug 2024 //
GLOBENEWSWIRE
Sutro Biopharma Reports Q2 2024 Results And Anticipated Milestones
13 Aug 2024 //
GLOBENEWSWIRE
Sutro Biopharma Appoints Dr. Barbara Leyman As Chief Business Officer
09 Jul 2024 //
GLOBENEWSWIRE
VGXI, Sutro Partner To Support Sutro`s Clinical Pipeline
03 Jun 2024 //
PR NEWSWIRE
Sutro Biopharma Q1 2024 Financials, Highlights, Milestones
13 May 2024 //
GLOBENEWSWIRE
Sutro Biopharma Initiates Part 2 of REFR?ME-O1 Trial
30 Apr 2024 //
GLOBENEWSWIRE
Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC
03 Apr 2024 //
PRESS RELEASE
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
02 Apr 2024 //
GLOBENEWSWIRE
Sutro Biopharma Reports Full Year 2023 Financial Results,
25 Mar 2024 //
GLOBENEWSWIRE
Sutro Biopharma to Participate in Upcoming Investor Conferences
06 Feb 2024 //
GLOBENEWSWIRE
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta
04 Jan 2024 //
GLOBENEWSWIRE
Sutro to Host Webcast Highlighting Multi-Cancer Opportunity for Luvelta
14 Dec 2023 //
GLOBENEWSWIRE
Sutro Bio Announces New Positive Data from the Compassionate Use of luvelta
11 Dec 2023 //
GLOBENEWSWIRE
Sutro Bio to Participate in the JMP Securities Hematology and Oncology Summit
04 Dec 2023 //
GLOBENEWSWIRE
Vaxcyte Enters into Manufacturing Rights Agreement with Sutro Biopharma
27 Nov 2023 //
GLOBENEWSWIRE
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
21 Nov 2023 //
GLOBENEWSWIRE
Sutro Biopharma Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations
16 Oct 2023 //
GLOBENEWSWIRE
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
19 Sep 2023 //
GLOBENEWSWIRE
Sutro Biopharma to Participate in Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Sutro Biopharma Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
26 Jun 2023 //
GLOBENEWSWIRE
Blackstone, Sutro ink royalty pact worth up to $390M biobucks
26 Jun 2023 //
FIERCE BIOTECH
Sutro Announces Presentation at ASCO Featuring Data for Luveltamab Tazevibulin
03 Jun 2023 //
GLOBENEWSWIRE
Sutro Biopharma to Participate in the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Sutro Biopharma Reports 1Q 2023 FYR Results, Business Highlights
15 May 2023 //
GLOBENEWSWIRE
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
08 May 2023 //
GLOBENEWSWIRE
Sutro Biopharma Announces the Departure of President of Research
27 Apr 2023 //
GLOBENEWSWIRE
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting ADC STRO-003
18 Apr 2023 //
GLOBENEWSWIRE
Sutro Biopharma Reports Full Reports 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Mar 2023 //
GLOBENEWSWIRE
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
28 Feb 2023 //
GLOBENEWSWIRE
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Feb 2023 //
GLOBENEWSWIRE
Sutro shells out update on ovarian cancer treatment, plans for pivotal trial
10 Jan 2023 //
ENDPTS
Sutro Biopharma Announces Update from STRO-002 Phase 1 Dose-Expansion Study
09 Jan 2023 //
GLOBENEWSWIRE
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Sutro Biopharma to Provide Data Update on STRO-002 and Plans
21 Dec 2022 //
GLOBENEWSWIRE
Sutro Biopharma & Vaxcyte Enter into Option Grant Agreement for the Development
20 Dec 2022 //
GLOBENEWSWIRE
Sutro Announces Presentation of STRO-002 Data from the Compassionate Use Program
10 Dec 2022 //
GLOBENEWSWIRE
Sutro Biopharma to Participate in Upcoming Investor Conferences
23 Nov 2022 //
GLOBENEWSWIRE
Sutro Biopharma Reports3Q 2022 Financial Results, Business Highlights
08 Nov 2022 //
GLOBENEWSWIRE
Sutro Biopharma Announces Oral Presentation at the 64th American of Hematology
03 Nov 2022 //
GLOBENEWSWIRE
Sutro Biopharma Announces Departure of Chief Medical Officer
24 Oct 2022 //
GLOBENEWSWIRE
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
01 Sep 2022 //
GLOBENEWSWIRE
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Aug 2022 //
GLOBENEWSWIRE
Sutro Biopharma Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
03 Aug 2022 //
GLOBENEWSWIRE
Sutro Biopharma Achieves “First in Human” Milestone in collaboration with Merck
26 Jul 2022 //
GLOBENEWSWIRE
Sutro Biopharma Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs – Presentation
20 Jul 2022 //
PRESS RELEASE
Sutro Biopharma Announces Virtual Deep Dive Research Forum
12 Jul 2022 //
GLOBENEWSWIRE
Astellas and Sutro Announce Worldwide Strategic Collaboration to Advance iADCs
27 Jun 2022 //
PRNEWSWIRE
